NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Gregory Bean, MD, PhD
Meena S. Moran, MD
Jessica S. Young, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Nan Chen, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee
Daiichi- Sankyo Co.: Consulting Fee
Guardant Health: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
SeaGen: Consulting Fee
Stemline Therapeutics, Inc.: Consulting Fee

William J. Gradishar, MD
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Carrick Therapeutics, Inc.: Scientific Advisor
Daiichi- Sankyo Co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
Stemline Therapeutics, Inc.: Scientific Advisor

Janice Lu, MD, PhD 
AstraZeneca Pharmaceuticals LP: Consulting Fee
Daiichi- Sankyo Co.: Consulting Fee

Halle C.F. Moore, MD
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Daiichi- Sankyo Co.: Grant/Research Support
Pfizer Inc.: Grant/Research Support
SeaGen: Grant/Research Support
Sermonix Pharmaceuticals: Grant/Research Support

Rita Nanda, MD
Arvinas: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Corcept Therapeutics, Incorporated: Grant/Research Support
Daiichi- Sankyo Co.: Consulting Fee
Exact Sciences Corporation: Consulting Fee
GE: Consulting Fee
Genentech/Roche: Grant/Research Support
Gilead Sciences, Inc.: Consulting Fee; Grant/Research Support
GSK: Grant/Research Support
Guardant Health: Consulting Fee
Merck & Co., Inc.: Consulting Fee; Grant/Research Support
Moderna, Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee; Grant/Research Support
OBI Pharma, Inc.: Consulting Fee; Grant/Research Support
Pfizer Inc.: Consulting Fee; Grant/Research Support
Relay Therapeutics: Grant/Research Support
sanofi-aventis U.S.: Consulting Fee
SeaGen: Consulting Fee; Grant/Research Support
Stemline Therapeutics, Inc.: Consulting Fee
Summit Therapeutics, Inc.: Consulting Fee
Sun Pharmaceutical Industries Inc.: Grant/Research Support
Taiho Pharmaceuticals Co., Ltd.: Grant/Research Support

Patricia A. Robinson, MD
Merck & Co., Inc.: Scientific Advisor
Pfizer Inc.: Scientific Advisor

Sarah Sammons, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support
Daiichi- Sankyo Co.: Consulting Fee
Eli Lilly and Company: Consulting Fee; Grant/Research Support
Foundation Medicine, Inc.: Consulting Fee
Gilead Sciences, Inc.: Consulting Fee
Incyclix Bio, LLC: Consulting Fee
Novartis Pharmaceuticals Corporation: Consulting Fee
Pfizer Inc.: Consulting Fee
Relay Therapeutics: Consulting Fee; Grant/Research Support
SeaGen: Grant/Research Support
Sermonix Pharmaceuticals: Consulting Fee; Grant/Research Support

Bryan P. Schneider, MD
Eli Lilly and Company: Scientific Advisor
Foundation Medicine, Inc.: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Pfizer Inc.: Grant/Research Support

Mary Lou Smith, JD, MBA
Bayer HealthCare: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Genentech, Inc.: Grant/Research Support
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Grant/Research Support
SeaGen: Grant/Research Support

Amye J. Tevaarwerk, MD
Tempus AI: Consulting Fee

Mei Wei, MD
Arvinas: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Merck & Co., Inc.: Scientific Advisor

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.